Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to
affect younger women, metastasise early despite optimal adjuvant treatment and carry a …

Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

Chemical probes are powerful reagents with increasing impacts on biomedical research.
However, probes of poor quality or that are used incorrectly generate misleading results. To …

The efficacy of therapeutics is dependent on a drug binding to its cognate target.
Optimization of target engagement by drugs in cells is often challenging, because drug …

Genomic instability is one of the most pervasive characteristics of tumour cells and is
probably the combined effect of DNA damage, tumour-specific DNA repair defects, and a …

Abstract Poly (ADP-ribose) polymerases (PARPs) are enzymes that transfer ADP-ribose
groups to target proteins and thereby affect various nuclear and cytoplasmic processes. The …

The genetic concept of synthetic lethality, in which the combination or synthesis of mutations
in multiple genes results in cell death, provides a framework to design novel therapeutic …

Triple‐negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular
subtypes that respond differentially to chemotherapy and targeted agents. The absence of …

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial
ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease …

Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …